Scaly skin diseases
Developed in collaboration with the University of Auckland Goodfellow Unit in 2007.
Images have been sourced from the following:
- Hon Assoc Prof Amanda Oakley
- The Department of Dermatology, Health Waikato
- Prof Raimo Suhonen (Finland)
Systemic therapy for psoriasisNext Previous
- Describe use of systemic therapies for psoriasis
Patients are considered to have severe psoriasis if they have extensive plaques, psoriasis on exposed sites or resulting in functional impairment (e.g. on hands preventing work, or feet preventing walking). ‘Severity’ may depend on the patient’s age, cultural background and occupation. Systemic therapy should be considered for those more than 10% to 20% body surface involvement, pustular psoriasis, erythrodermic psoriasis, psoriatic arthritis and more localized, recalcitrant psoriasis. This is true for children as well as adults, but systemic treatment is rarely necessary in children or adolescents.
The PASI (Psoriasis Area and Severity Index) was set up as an attempt to assess the severity of psoriasis for clinical trials. The percentage of patients achieving a 50% or 75% reduction in PASI is used to evaluate the efficacy of new drugs. The PASI combines assessments of the percentage of body area affected, erythema, desquamation, and induration to produce a score ranging from 0 (no psoriasis) to 72 (the most severe case of psoriasis).
Methotrexate, a synthetic analogue of folic acid, is the most widely used systemic agent in the treatment of psoriasis and psoriatic arthritis. It is probably effective because of its immunosuppressive effects. It is also used to treat various malignancies because it has antimetabolite activity.
Methotrexate has the following actions:
- Competitive inhibitor of the enzyme dihydrofolate reductase
- Inhibits DNA synthesis and cell division
- Inhibits replication and function of T and B cells
- Suppresses the secretion of cytokines such as interleukin 1, interferon-g, and tumour necrosis factor.
- Suppresses epidermal cell division in psoriasis
Pharmaceutical schedule funding in New Zealand is restricted to specialists or requires their approval. Methotrexate is administered either as a single weekly dose, usually orally, or as an intermittent oral schedule of three divided doses up to about 25mg over a 36-hour period once a week. Folic acid 1-5mg daily may help reduce adverse effects such as nausea and macrocytic anemia. Safety should be monitored by regular blood count, renal and liver function tests.
The aminoterminal peptide of type 3 procollagen (P3NP) can be measured in the serum and is a marker of active liver fibrosis. should be obtained prior to starting treatment and repeated every 3 to 6 months. Some patients require liver biopsy; current evidence indicates liver biopsy is not necessary if the P3NP collagen level remains consistently below the upper limit of normal, <4.2 µg/L.
Adverse reactions include:
- Gastrointestinal complaints
- Malaise, headaches
- Mouth ulceration
- Pulmonary fibrosis
- Bone marrow suppression and macrocytic anaemia
- Liver damage including fibrosis and cirrhosis
- Important drug interactions (refer to standard texts).
Acitretin is an oral retinoid (vitamin A derivative) used to treat psoriasis and other disorders of keratinisation. It appears to thin down thick psoriatic plaques and reduce inflammation. Acitretin is especially useful for pustular psoriasis, erythrodermic psoriasis and palmoplantar keratoderma.
The usual dose is 10-50mg daily, and should be prescribed by a dermatologist. Since March 2009, acitretin has required Special Authority application for funding in New Zealand; restrictions apply. It can be combined with other topical or systemic therapy and is especially useful with phototherapy. Monitoring requires pregnancy testing in females, complete blood count, lipids and liver function tests.
Adverse effects often limit tolerability and include:
- Teratogenicity (causes major human fetal abnormalities): acitretin must not be used by females who are pregnant or who intend to become pregnant during therapy or at any time for at least two years following the discontinuation of therapy
- Mucocutaneous adverse effects: dry fragile lips, skin, nose and eyes, peeling palms and soles, hair loss, thinned fragile nails, delayed wound healing
- Arthralgias, myalgias, raised intracranial pressure (oral retinoids must not be taken with tetracycline or tetracycline derivatives), decreased night vision
- Hepatotoxicity (rare) and hypertriglyceridaemia (more common).
Ciclosporin is an effective immunosuppressive agent used to prevent allograft rejection. It is very effective in the treatment of all forms of psoriasis.
Ciclosporin is a calcinerin inhibitor, which inhibits T cell activation and so reduces the production of cytokines especially IL-2 and interferon-g.
In New Zealand, it is funded for severe psoriasis on Special Authority application using doses of 2.5 to 5mg/kg/day. Renal function and blood pressure must be carefully monitored and may require dose reductions or treatment interruptions.
Adverse effects include:
- Hypertension (may be treated using calcium channel blockers)
- Gastrointestinal symptoms
- Headache, myalgias, arthralgias, paresthesias and fatigue
- Hypertrichosis and gingival hypertrophy
- Induction of skin cancer, especially squamous cell carcinoma
- Risk of lymphoma
- Numerous drug interactions.
Other immunosuppressive agents
Although less effective that methotrexate and ciclosporin, the following immunosuppressive medications are sometimes used to treat psoriasis:
- Mycophenolic mofetil
Biological response mediators
Treatment with several targeted drugs appears effective for psoriasis in many patients and is relatively safe. The expense of treatment limits their use.
Alefacept binds to CD2 on activated memory T cells. One-third of those treated once weekly with IM or IV alefacept achieve 75% reduction in PASI, and two-thirds achieve 50% reduction. Treatment may not be required again for some months. It appears to have few adverse effects.
Efalizumab (anti-CD11a) is a humanized monoclonal antibody. One-quarter of those treated once weekly with IV efalizumab achieve 75% reduction in PASI, and half achieve 50% reduction.
Infliximab is an anti-TNFa chimeric IgG1 monoclonal antibody composed of human constant and murine variable regions. It is currently registered for treating Crohn disease, severe rheumatoid arthritis, psoriatic arthritis and psoriasis. It is quickly very effective in controlling psoriasis (up to 80% achieve 75% reduction in PASI) and may result in prolonged remissions. It is delivered IV three times over six weeks and then every 8 weeks. Concurrent treatment with methotrexate is recommended to prevent formation of anti-infliximab antibodies. Untreated tuberculosis must be eliminated prior to treatment.
Etanercept is a fusion protein, which acts as a competitive inhibitor of TNF-a. Subcutaneous etanercept is currently approved for psoriatic arthritis, rheumatoid arthritis and moderate to severe psoraisis. Etanercept may be associated with activation of tuberculosis but otherwise appears to have an excellent safety profile.
Describe monitoring necessary when ciclosporin is prescribed for psoriasis